- $10.08bn
- $10.67bn
- $1.27bn
U.S. STOCKS ON THE MOVE-Marvell Technology, Tempus AI, Energy Vault
Tempus AI rises as it expands cancer research partnership with Gilead
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
Tempus AI rises after study shows AI-driven alerts improve heart valve treatment
Brief: Tempus And Medtronic Announce Alert Trial Results Showing Ai-Driven Ehr Notifications Improve Treatment For Significant Valvular Heart Disease
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
Tempus AI rises after partnering with Daiichi Sankyo for cancer drug
Brief: Tempus And Blood Cancer United® Announce Collaboration To Develop One Of The Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
Brief: Tempus Announces Strategic Collaboration Agreement With Merck To Accelerate Ai-Driven Precision Medicine
Tempus AI's Q4 revenue up 83%, beating estimates
U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners
Tempus AI climbs on $1.1 billion contract value
Brief: Tempus Says It Achieves Record Total Contract Value Exceeding $1.1 Billion
Brief: Tempus AI Inc Says Qtrly Revenue Of Approximately $367 Million
Brief: Tempus AI Inc - Selected By ARPA-H To Provide CRO And Testing Services For The Adapt Program
Brief: Renalytix Announces Collaboration With Tempus To Advance Intelligent Risk Assessment In Diabetic Kidney Disease